1. Unorthodox Parenteral β-Lactam and β-Lactamase Inhibitor Combinations: Flouting Antimicrobial Stewardship and Compromising Patient Care.
- Author
-
Palwe S, Veeraraghavan B, Periasamy H, Khobragade K, and Kharat AS
- Subjects
- Acinetobacter Infections drug therapy, Acinetobacter baumannii drug effects, China, Drug Combinations, Drug Resistance, Multiple, Bacterial, Enterobacteriaceae drug effects, Enterobacteriaceae Infections drug therapy, Humans, India, Microbial Sensitivity Tests, Patient Care, Pseudomonas Infections drug therapy, Pseudomonas aeruginosa drug effects, beta-Lactamase Inhibitors therapeutic use, Anti-Bacterial Agents therapeutic use, Antimicrobial Stewardship, Cephalosporins therapeutic use, Drug Misuse, Inappropriate Prescribing, Sulbactam therapeutic use, Tazobactam therapeutic use
- Abstract
In India and China, indigenous drug manufacturers market arbitrarily combined parenteral β-lactam and β-lactamase inhibitors (BL-BLIs). In these fixed-dose combinations, sulbactam or tazobactam is indiscriminately combined with parenteral cephalosporins, with BLI doses kept in ratios similar to those for the approved BL-BLIs. Such combinations have been introduced into clinical practice without mandatory drug development studies involving pharmacokinetic/pharmacodynamic, safety, and efficacy assessments being undertaken. Such unorthodox combinations compromise clinical outcomes and also potentially contribute to resistance development., (Copyright © 2020 American Society for Microbiology.)
- Published
- 2020
- Full Text
- View/download PDF